Гистиоцитоз из клеток Лангерганса у детей: обзор литературы
https://doi.org/10.15690/vsp.v22i1.2520
Аннотация
Представлена актуальная информация о развитии и течении гистиоцитоза из клеток Лангерганса у детей. Описаны современные концепции патогенеза заболевания, принципы оценки тяжести и стратификации пациентов в группы риска, а также особенности клинического течения. Обобщены и проанализированы современные подходы к лечению заболевания с использованием таргетной терапии.
Об авторах
Е. А. Бурцев
Морозовская ДГКБ ДЗМ
Россия
Раскрытие интересов:
Россия
Бурцев Евгений Андреевич, врач-гематолог отделения трансплантации костного мозга и гемопоэтических стволовых клеток,
119049, Москва, 4-й Добрынинский пер., д. 1/9
Раскрытие интересов:
Авторы статьи подтвердили отсутствие конфликта интересов, о котором необходимо сообщить.
Г. О. Бронин
Морозовская ДГКБ ДЗМ
Россия
Раскрытие интересов:
Россия
Москва
Раскрытие интересов:
Авторы статьи подтвердили отсутствие конфликта интересов, о котором необходимо сообщить.
Список литературы
1. Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135(16):1319–1331. doi: https://doi.org/10.1182/BLOOD.2019000934
2. Минков М. Эволюция лечения детей с гистиоцитозом из клеток Лангерганса // Педиатрия. Журнал им. Г.Н. Сперанского. — 2021. — Т. 100. — № 3. — С. 107–120. — doi: https://doi.org/10.24110/0031-403x-2021-100-3-107-120
3. Alston RD, Tatevossian RG, McNally RJQ, et al. Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr Blood Cancer. 2007;48(5): 555–560. doi: https://doi.org/10.1002/PBC.20884
4. Aricò M. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy. Br J Haematol. 2016;173(5): 663–670. doi: https://doi.org/10.1111/BJH.13955
5. Han D, Li F, Yahya WH, et al. Multisystem Langerhans Cell Histiocytosis in Younger Infants First Presenting in Skin: A Case Series. J Pers Med. 2022;12(7):1024. doi: https://doi.org/10.3390/jpm12071024
6. Liu H, Stiller CA, Crooks CJ, et al. Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019. Br J Haematol. 2022; 199(5):728–738. doi: https://doi.org/10.1111/bjh.18459
7. Белова В.Ю., Спичак И.И. Гистиоцитоз из клеток Лангерганса у детей Челябинской области (1995–2018): заболеваемость, клинические формы, программы лечения, выживаемость // Педиатрический вестник Южного Урала. — 2020. — № 1. — 59–65. — doi: https://doi.org/10.34710/chel.2020.61.36.009
8. Ribeiro KB, Degar B, Antoneli CBG, et al. Ethnicity, race, and socioeconomic status influence incidence of langerhans cell histiocytosis. Pediatr Blood Cancer. 2015;62(6):982–987. doi: https://doi.org/10.1002/PBC.25404
9. Lorillon G, Tazi A. How I manage pulmonary Langerhans cell histiocytosis. Eur Respir Rev. 2017;26(145):170070. doi: https://doi.org/10.1183/16000617.0070-2017
10. Ma J, Laird JH, Chau KW, et al. Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. Cancer Med. 2019;8(1):58–66. doi: https://doi.org/10.1002/CAM4.1844
11. Bagnasco F, Zimmermann SY, Egeler RM, et al. Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients. Eur J Cancer. 2022;172:138–145. doi: https://doi.org/10.1016/J.EJCA.2022.03.036
12. Feng C, Li Y, Ke H, et al. Immune Microenvironment in Langerhans Cell Histiocytosis: Potential Prognostic Indicators. Front Oncol. 2021;11:631682. doi: https://doi.org/10.3389/FONC.2021.631682
13. Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med. 2007;4(8):1374–1384. doi: https://doi.org/10.1371/JOURNAL.PMED.0040253
14. Morimoto A, Oh Y, Shioda Y, et al. Recent advances in Langerhans cell histiocytosis. Pediatr Int. 2014;56(4):451–461. doi: https://doi.org/10.1111/PED.12380
15. Badalian-Very G, Vergilio J-A, Degar BA, et al. MYELOID NEOPLASIA Brief report Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–1923. doi: https://doi.org/10.1182/blood-2010-04-279083
16. Pakneshan S, Salajegheh A, Smith RA, Lam AKY. Clinicopathological relevance of BRAF mutations in human cancer. Pathology. 2013;45(4):346–356. doi: https://doi.org/10.1097/PAT.0b013e328360b61d
17. Yaeger R, Corcoran RB. Targeting Alterations in the RAF-MEK Pathway. Cancer Discov. 2019;9(3):329–341. doi: https://doi.org/10.1158/2159-8290.CD-18-1321
18. Thevakumaran N, Lavoie H, Critton DA, et al. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Nat Struct Mol Biol. 2015;22(1):37–43. doi: https://doi.org/10.1038/NSMB.2924
19. Brown NA, Furtado LV, Betz BL, et al. Brief Report MYELOID NEOPLASIA High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10): 1655–1658. doi: https://doi.org/10.1182/blood-2014-05
20. Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activa ting ARAF mutations in Langerhans cell histiocytosis. Blood. 2014;123(20): 3152–3155. doi: https://doi.org/10.1182/BLOOD-2013-06-511139
21. Ali S, Bailey M, Stephens P, et al. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight. 2017;2(3):e89473. doi: https://doi.org/10.1172/jci.insight.89473
22. Rollins BJ. Genomic Alterations in Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am. 2015;29(5):839–851. doi: https://doi.org/10.1016/J.HOC.2015.06.004
23. Gulati N, Allen CE. Langerhans cell histiocytosis: Version 2021. Hematol Oncol. 2021;39(Suppl 1):15–23. doi: https://doi.org/10.1002/HON.2857
24. Berres M-L, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol. 2014;169(1):3–13. doi: https://doi.org/10.1111/bjh.13247
25. Berres ML, Lim KPH, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669–683. doi: https://doi.org/10.1084/JEM.20130977
26. Mass E, Jacome-Galarza CE, Blank T, et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature. 2017;549(7672):389–393. doi: https://doi.org/10.1038/nature23672
27. McClain KL, Picarsic J, Chakraborty R, et al. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018;124(12): 2607–2620. doi: https://doi.org/10.1002/CNCR.31348
28. Haupt R, Minkov M, Astigarraga I, et al. Langerhans Cell Histiocytosis (LCH): Guidelines for Diagnosis, Clinical Work-Up, and Treatment for Patients Till the Age of 18 Years. Pediatr Blood Cancer. 2013;60(2):175–184. doi: https://doi.org/10.1002/pbc.24367
29. Jezierska M, Stefanowicz J, Romanowicz G, et al. Langerhans cell histiocytosis in children — A disease with many faces. Recent advances in pathogenesis, diagnosticexaminations and treatment. Postepy Dermatol Alergol. 2018;35(1):6–17. doi: https://doi.org/10.5114/pdia.2017.67095
30. Khung S, Budzik JF, Amzallag-Bellenger E, et al. Skeletal involvement in Langerhans cell histiocytosis. Insights Imaging. 2013; 4(5):569–579. doi: https://doi.org/10.1007/S13244-013-0271-7
31. Azouz EM, Saigal G, Rodriguez MM, Podda A. Langerhans’ cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol. 2005;35(2):103–115. doi: https://doi.org/10.1007/S00247-004-1262-0
32. Abdelaal AHK, Sedky M, Gohar S, et al. Skeletal involvement in children with Langerhans cell histiocytosis: healing, complications, and functional outcome. SICOT-J. 2020;6:28. doi: https://doi.org/10.1051/SICOTJ/2020024
33. Allen CE, Flores R, Rauch R, et al. Neurodegenerative Central Nervous System Langerhans Cell Histiocytosis and Coincident Hydrocephalus: Treated with Vincristine/Cytosine Arabinoside. Pediatr Blood Cancer. 2010;54(3):416–423. doi: https://doi.org/10.1002/PBC.22326
34. Luz J, Zweifel D, Hüllner M, et al. Oral manifestation of Langerhans cell histiocytosis: a case report. BMC Oral Health. 2018;18(1): 106. doi: https://doi.org/10.1186/S12903-018-0568-5
35. Lakatos K, Sterlich K, Pötschger U, et al. Langerhans Cell Histiocytosis of the Orbit: Spectrum of Clinical and Imaging Findings. J Pediatr. 2021;230:174–181.e1. doi: https://doi.org/10.1016/J.JPEDS.2020.10.056
36. Parikh SN, Desai VR, Gupta A, Anton CG. Langerhans Cell Histiocytosis of the Clavicle in a 13-Year-Old Boy. Case Rep Orthop. 2014;2014:510287. doi: https://doi.org/10.1155/2014/510287
37. Song YS, Lee IS, Yi JH, et al. Radiologic findings of adult pelvis and appendicular skeletal Langerhans cell histiocytosis in nine patients. Skeletal Radiol. 2011;40(11):1421–1426. doi: https://doi.org/10.1007/S00256-010-1078-Y
38. Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S82–S89. doi: https://doi.org/10.1016/J.BBMT.2009.11.014
39. Morren MA, Vanden Broecke K, Vangeebergen L, et al. Diverse Cutaneous Presentations of Langerhans Cell Histiocytosis in Children: A Retrospective Cohort Study. Pediatr Blood Cancer. 2016;63(3):486–492. doi: https://doi.org/10.1002/PBC.25834
40. Simko SJ, Garmezy B, Abhyankar H, et al. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 2014;165(5):990–996. doi: https://doi.org/10.1016/J.JPEDS.2014.07.063
41. Battistella M, Fraitag S, Teillac DH, et al. Neonatal and early infantile cutaneous langerhans cell histiocytosis: comparison of self-regressive and non-self-regressive forms. Arch Dermatol. 2010;146(2):149–156. doi: https://doi.org/10.1001/ARCHDERMATOL.2009.360
42. Lau L, Krafchik B, Trebo MM, Weitzman S. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer. 2006;46(1):66–71. doi: https://doi.org/10.1002/PBC.20479
43. Chander R, Jaykar K, Varghese B, et al. Pulmonary disease with striking nail involvement in a child. Pediatr Dermatol. 2008;25(6): 633–634. doi: https://doi.org/10.1111/J.1525-1470.2008.00788.X
44. Yadav SP, Kharya G, Mohan N, et al. Langerhans cell histiocytosis with digestive tract involvement. Pediatr Blood Cancer. 2010;55(4):748–753. doi: https://doi.org/10.1002/PBC.22663
45. Singhi AD, Montgomery EA. Gastrointestinal tract langerhans cell histiocytosis: A clinicopathologic study of 12 patients. Am J Surg Pathol. 2011;35(2):305–310. doi: https://doi.org/10.1097/PAS.0B013E31820654E4
46. Barclay M, Devaney R, Bhatt JM. Paediatric pulmonary Langerhans cell histiocytosis. Breathe (Sheff). 2020;16(2):200003. doi: https://doi.org/10.1183/20734735.0003-2020
47. Евсеев Д.А., Калинина И.И., Ускова Н.Г. и др. Применение превентивного плевродеза у пациента с гистиоцитозом из клеток Лангерганса с поражением легких // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. — 2018. — Т. 17. — № 3. — С. 74–80. — doi: https://doi.org/10.24287/1726-1708-2018-17-3-74-80
48. Ronceray L, Pötschger U, Janka G, et al. Pulmonary involvement in pediatric-onset multisystem Langerhans cell histiocytosis: effect on course and outcome. J Pediatr. 2012;161(1):129–133.e1–3. doi: https://doi.org/10.1016/J.JPEDS.2011.12.035
49. Elia D, Torre O, Cassandro R, et al. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review. Eur J Intern Med. 2015;26(5):351–356. doi: https://doi.org/10.1016/J.EJIM.2015.04.001
50. Bano S, Chaudhary V, Narula MK, et al. Pulmonary Langerhans cell histiocytosis in children: a spectrum of radiologic findings. Eur J Radiol. 2014;83(1):47–56. doi: https://doi.org/10.1016/J.EJRAD.2013.04.044
51. Abba ME, Żegleń S, Łącka M, et al. Lung Transplant in a Patient With Multifocal Langerhans Cell Histiocytosis After Chemotherapy With Cladribine: A Case Report. Transplant Proc. 2022;54(4): 1177–1179. doi: https://doi.org/10.1016/J.TRANSPROCEED.2022.02.037
52. Nezelof C, Frileux‐Herbet F, Cronier‐Sachot J. Disseminated histiocytosis X: analysis of prognostic factors based on a retrospective study of 50 cases. Cancer. 1979;44(5):1824–1838. doi: https://doi.org/10.1002/1097-0142(197911)44:53.0.co;2-j
53. Braier J, Chantada G, Rosso D, et al. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution. Pediatr Hematol Oncol. 1999;16(5):377–385. doi: https://doi.org/10.1080/088800199276921
54. Minkov M, Pötschger U, Grois N, et al. Bone marrow assessment in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;49(5):694–698. doi: https://doi.org/10.1002/PBC.21227
55. Donadieu J, Chalard F, Jeziorski E. Medical management of langerhans cell histiocytosis from diagnosis to treatment. Expert Opin Pharmacother. 2012;13(9):1309–1322. doi: https://doi.org/10.1517/14656566.2012.688028
56. Braier J, Ciocca M, Latella A, et al. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell Histiocy tosis. Med Pediatr Oncol. 2002;38(3):178–182. doi: https://doi.org/10.1002/MPO.1306
57. Yi X, Han T, Zai H, et al. Liver involvement of Langerhans’ cell histiocytosis in children. Int J Clin Exp Med. 2015;8(5):7098.
58. Grana N. Langerhans cell histiocytosis. Cancer Control. 2014; 21(4):328–334. doi: https://doi.org/10.1177/107327481402100409
59. Hong L, Sun G, Peng L, et al. Solated Langerhans cell histiocytosis of the spleen: A case report. Medicine (Baltimore). 2018;97(38): e12378. doi: https://doi.org/10.1097/MD.0000000000012378
60. Edelweiss M, Medeiros LJ, Suster S, Moran CA. Lymph node involvement by Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical study of 20 cases. Hum Pathol. 2007; 38(10):1463–1469. doi: https://doi.org/10.1016/J.HUMPATH.2007.03.015
61. Yeh EA, Greenberg J, Abla O, et al. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatr Blood Cancer. 2018;65(1). doi: https://doi.org/10.1002/PBC.26784
62. Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156(6):873–881. e1. doi: https://doi.org/10.1016/J.JPEDS.2010.03.001
63. Crois N, Pötschger U, Prosch H, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46(2):228–233. doi: https://doi.org/10.1002/PBC.20425
64. Nanduri VR, Bareille P, Pritchard J, Stanhope R. Growth and endocrine disorders in multisystem Langerhans’ cell histiocytosis. Clin Endocrinol (Oxf). 2000;53(4):509–515. doi: https://doi.org/10.1046/J.1365-2265.2000.01125.X
65. Chaudhary V, Bano S, Aggarwal R, et al. Neuroimaging of Langerhans cell histiocytosis: a radiological review. Jpn J Radiol. 2013;31(12):786–796. doi: https://doi.org/10.1007/S11604-013-0254-0
66. Gabbay LB, Leite C da C, Andriola RS, et al. Histiocytosis: a review focusing on neuroimaging findings. Arq Neuropsiquiatr. 2014;72(7):548–558. doi: https://doi.org/10.1590/0004-282X20140063
67. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr. 2001;138(5):728–734. doi: https://doi.org/10.1067/mpd.2001.111331
68. Gadner H, Grois N, Pötschger U, et al. Improved outcome in multi system Langerhans cell histiocytosis is associated with therapy in ten sification. Blood. 2008;111(5):2556–2562. doi: https://doi.org/10.1182/blood-2007-08-106211
69. Grois N, Prayer D, Prosch H, Lassmann H. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain. 2005;128 (Pt 4):829–838. doi: https://doi.org/10.1093/BRAIN/AWH403
70. Gadner H, Heitger A, Ritter J, et al. Langerhans cell histiocytosis in childhood--results of the DAL-HX 83 study. Klin Padiatr. 1987;199(3):173–182. doi: https://doi.org/10.1055/s-2008-1026785
71. Ceci A, De Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X ’83 study. Med Pediatr Oncol. 1993;21(4):259–264. doi: https://doi.org/10.1002/MPO.2950210405
72. Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006–5014. doi: https://doi.org/10.1182/blood-2012-09
73. Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs. 2011;13(2):75–86. doi: https://doi.org/10.2165/11538540-000000000-00000
74. Héritier S, Jehanne M, Leverger G, et al Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis JAMA Oncol. 2015;1(6):836–838. doi: https://doi.org/10.1001/jamaoncol.2015.0736
75. Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol. 2019;37(31): 2857–2865. doi: https://doi.org/10.1200/JCO.19.00456
76. Evseev D, Kalinina I, Raykina E, et al. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cellfree circulating DNA. Int J Hematol. 2021;114(6):725–734. doi: https://doi.org/10.1007/s12185-021-03205-8
77. Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms HHS Public Access. Nature. 2019;567:521–4. doi: https://doi.org/10.1038/s41586-019-1012-y
78. Бурцев Е.А. Бронин Г.О. MEK-ингибиторы в терапии гистиоцитоза из клеток Лангерганса // Российский журнал детской гематологии и онкологии. — 2022. — Т. 9. — № 3. — С. 42–47. — doi: https://doi.org/10.21682/2311-1267-2022-9-3-42-47
79. Awada G, Seremet T, Fostier K, et al. Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition. Blood Adv. 2018;2(16):2156–2158. doi: https://doi.org/10.1182/BLOODADVANCES.2018021782
80. Dhall G, Finlay JL, Dunkel IJ, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer. 2008;50(1):72–79. doi: https://doi.org/10.1002/PBC.21225
81. Abla O, Weitzman S, Minkov M, et al. Diabetes insipidus in Langerhans cell histiocytosis: When is treatment indicated? Pediatr Blood Cancer. 2009;52(5):555–556. doi: https://doi.org/10.1002/PBC.21924
82. Abla O, Palmert MR. Reversal of LCH-related diabetes insipidus and reappearance of posterior pituitary bright spot with low-dose chemotherapy. Pediatr Blood Cancer. 2012;59(1):201–202. doi: https://doi.org/10.1002/PBC.24061
83. Imashuku S, Okazaki N, Nakayama M, et al. Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy. Pediatr Blood Cancer. 2008;50(2):308–311. doi: https://doi.org/10.1002/PBC.21259
84. Gavhed D, Laurencikas E, Åkefeldt SO, Henter JI. Fifteen years of treatment with intravenous immunoglobulin in central nervous system Langerhans cell histiocytosis. Acta Paediatr. 2011;100(7):e36–e39. doi: https://doi.org/10.1111/J.1651-2227.2010.02125.X
85. Idbaih A, Donadieu J, Barthez MA, et al. Retinoic acid therapy in “degenerative-like” neuro-langerhans cell histiocytosis: a pros pective pilot study. Pediatr Blood Cancer. 2004;43(1):55–58. doi: https://doi.org/10.1002/PBC.20040
86. Euskirchen P, Haroche J, Emile JF, et al. Complete remission of critical neurohistiocytosis by vemurafenib. Neurol Neuroimmunol Neuroinflammation. 2015;2(2):e78. doi: https://doi.org/10.1212/NXI.0000000000000078
87. Sveijer M, Von Bahr Greenwood T, Jädersten M, et al. Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma. Br J Haematol. 2022;198(4): 721–728. doi: https://doi.org/10.1111/bjh.18247
88. Minkov M. An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy. Expert Opin Pharmacother. 2018;19(3):233–42. doi: https://doi.org/10.1080/14656566.2018.1429405
89. Волкова Е.Н., Бронин Г.О., Высоцкая Т.А. и др. Результаты ретроспективного моноцентрового исследования гистиоцитоза из клеток лангерганса у детей // Педиатрия. Журнал им. Г.Н. Сперанского. — 2009. — Т. 87. — № 4. — С. 33–40.
90. Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society — Late Effects Study Group. Pediatr Blood Cancer. 2004;42(5):438–444. doi: https://doi.org/10.1002/PBC.20021
91. Willis B, Ablin A, Weinberg V, et al. Disease course and late sequelae of Langerhans’ cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol. 1996;14(7): 2073–2082. doi: https://doi.org/10.1200/JCO.1996.14.7.2073
92. Гурьева О.Д., Валиев Т.Т., Павловская А.И. Гистиоцитарные опухоли: современные аспекты патогенеза, классификации, диагностики и лечения // Онкогематология. — 2022. — Т. 17. — № 1. — С. 10–25. — doi: https://doi.org/10.17650/1818
93. Chow TW, Leung WK, Cheng FWT, et al. Late outcomes in children with Langerhans cell histiocytosis. Arch Dis Child. 2017;102(9):830– 835. doi: https://doi.org/10.1136/ARCHDISCHILD-2016-312185
94. Rigaud C, Barkaoui MA, Thomas C, et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol. 2016;174(6):887–898. doi: https://doi.org/10.1111/BJH.14140
95. Di Iorgi N, Allegri AEM, Napoli F, et al. Central diabetes insipidus in children and young adults: etiological diagnosis and long-term outcome of idiopathic cases. J Clin Endocrinol Metab. 2014;99(4):1264–1272. doi: https://doi.org/10.1210/JC.2013-3724
96. Nanduri VR, Pritchard J, Chong WK, et al. Labyrinthine involvement in Langerhans’ cell histiocytosis. Int J Pediatr Otorhinolaryngol. 1998;46(1-2):109–115. doi: https://doi.org/10.1016/S0165-5876(98)00116-5
Рецензия
Для цитирования:
Бурцев Е.А., Бронин Г.О. Гистиоцитоз из клеток Лангерганса у детей: обзор литературы. Вопросы современной педиатрии. 2023;22(1):13-22. https://doi.org/10.15690/vsp.v22i1.2520
For citation:
Burtsev E.A., Bronin G.O. Langerhans Cell Histiocytosis in Children: Literature Review. Current Pediatrics. 2023;22(1):13-22. (In Russ.) https://doi.org/10.15690/vsp.v22i1.2520
Просмотров:
885
Послать статью по эл. почте 
